Advances in Multiple Myeloma From ASH 2020

Joseph Mikhael, MD


December 28, 2020

Dr Joseph Mikhael, a leading expert in myeloma, discusses his pick of key studies in multiple myeloma presented at the 2020 American Society of Hematology (ASH) Annual Meeting and Exposition.

He starts off with three studies in transplant-eligible patients with newly diagnosed disease: an updated analysis from the phase 2 GRIFFIN trial, a follow-up analysis of early vs late autologous stem cell transplant in the IFM 2009 trial, and a survival analysis from the Forte trial.

He next looks at studies addressing early relapse, discussing the phase 3 APOLLO trial of subcutaneous daratumumab plus pomalidomide and dexamethasone vs pomalidomide and dexamethasone alone in relapsed/refractory multiple myeloma. The triple therapy significantly reduced the risk for progression or death.

Dr Mikhael moves on to two approaches in patients who experience late relapse. First up is CAR T-cell therapy, with updated results from the phase 1 CRB-401 study. He follows this with a discussion of the phase 1b/2 study CARTITUDE-1. Both trials showed deep and durable responses even in heavily pretreated patients.

Finally, bispecific antibody therapies take center stage. From among the many studies with these promising agents presented at ASH 2020, Dr Mikhael selects a study of the bispecific BCMA x CD3 antibody teclistamab and a phase 1 first-in-human study of AMG 701 for special consideration.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.